Join Our Mailing List:
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
Featured Events
View All Events
Ann C. Raldow, M.D., M.P.H.
Research performed at: UCLA's Jonsson Comprehensive Cancer Center
Specialty/Research Area: Radiation Oncology, Gastrointestinal Oncology
Award Year: 2018
Career Summary: Dr. Ann Raldow is an Assistant Professor in the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA. Dr. Raldow graduated from Princeton University with a Bachelor of Arts degree in molecular biology. She earned her medical degree at the Yale University School of Medicine. After finishing her internship at Memorial Sloan Kettering Cancer Center, Dr. Raldow completed her residency at the Harvard Radiation Oncology Program, where she trained at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Medical Center, Boston Children’s Hospital and Beth Israel Deaconess Medical Center. Dr. Raldow also obtained a Master of Public Health degree from the Harvard T.H. Chan School of Public Health. Dr. Raldow specializes in the treatment of gastrointestinal malignancies. She has expertise in intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and other advanced techniques in radiation therapy. 

Year STOP CANCER Award was received: 2018 Richard Merkin, M.D. Seed Grant
Description of research performed: Dr. Raldow’s research focuses on therapeutic decision making, quality of life, and health outcomes assessment. She has a special interest in studying the cost-effectiveness of cancer care.

Results of research: There is a pressing need for cost-effectiveness studies within the field of radiation oncology; to date, only a handful of these types of analyses have been published. As our treatments become more technical and expensive, it is our responsibility to prove that these treatments lead to benefits that warrant the increased cost and that limited resources are allocated appropriately. As such, Dr. Raldow is involved in studying the cost-effectiveness of using different approaches to treating gastrointestinal malignancies. 

Dr. Raldow is also interested in studying the cost-effectiveness of genomic assays. The past decade has seen considerable interest in the use of genomic assays to improve treatment selection for patients with cancer by better characterizing the biologic potential of tumors than can be accomplished using classic characteristics alone. However, such genomic assays are expensive, and the optimal strategy for their use remains unclear. When completed, Dr. Raldow’s projects will give better insight into the most cost-effective ways of using genomic assays, paving the way for personalized approaches to treating patients with cancer. 

STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2018 STOP CANCER. All Rights Reserved. | Privacy Policy